Close
Close

Anti-GPC3 (YP7)-Megf10 CAR THP1 (CARTHP-W0802)

 Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The anti-GPC3 chimeric antigen receptor (CAR) THP1 cell line is a stable cell line developed using anti-GPC3 CAR lentivirus transfection. This transfected CAR lentiviral vector is constructed to express a scfv of anti-GPC3 antibody (YP7) linked to Megf10 signaling domains.The anti-GPC3 CAR engineered THP1 cells can be used to be differentiated into macrophage cells for in vitro or in vivo phagocytosis studies. This CAR-THP1 cell line product can be used for the researches of HCC, squamous cell carcinoma (SCC).

Specific Inquiry

  • Size:
  • Marker:
  • Positive rate:
  Add to Cart

Details

  • Target
  • GPC3
  • Cell Type
  • THP1
  • Cell Background
  • THP-1 is a human leukemia monocytic cell line, which has been extensively used to study monocyte/macrophage functions, mechanisms, signaling pathways, and nutrient and drug transport. This cell line has become a common model to estimate modulation of monocyte and macrophage activities. CAR engineered THP1 cells can be differentiated into macrophages using PMA (Phorbol 12-myristate 13-acetate). Once differentiated (M0 macrophages), they were incubated with IL-4 and IL-13 in order to obtain M2 polarized macrophages or with IFN-gamma and LPS for classical macrophage activation (M1).
  • Targeting Diseases
  • HCC, squamous cell carcinoma (SCC)
  • CAR Expression
  • Positive
  • CAR Positive Rate
  • >95% for stable cell pool (please submit an inquiry if single clonal cell line is needed.)
  • Cell Viability
  • >90%
  • Mycoplasma Testing
  • Negative
  • Handling Notes
  • Frozen cells should be thawed immediately upon receipt and grown according to handling procedure to ensure cell viability and proper assay performance.
    Note: Do not freeze the cells upon receipt as it may result in irreversible damage to the cell line.
    Disclaimer: We cannot guarantee cell viability if the cells are not thawed immediately upon receipt and grown according to handling procedure.
  • Safety Consideration
  • Biosafety Level 1
  • Restriction
  • Research use only
  • Size
  • 2 million cells*2 vials
  • Storage
  • Frozen cells should be stored in a liquid nitrogen tank (-150°C~-190°C) for long term.

CAR Components

  • Promoter
  • EF1a
  • scFv
  • YP7
  • Hinge
  • CD8
  • TM
  • CD8
  • ICD
  • Megf10
  • Marker
  • GFP or N/A
  • Receptor Construction
  • scFv-hinge(CD8)-TM(CD8)-ICD(Megf10)
  • Discription of Signaling Cassetes
  • Megf10:
    Megf10 is used as the CAR intracellular signaling domain. As a phagocytosis receptor, Megf10 has cytosolic Immunoreceptor Tyrosine-based Activation Motifs (ITAMs) that are phosphorylated by Src family kinases. Based on this mechanism, Megf10 signaling can induce macrophage phagocytosis which has been demonstrated in the published article.
    It is a membrane receptor involved in phagocytosis by macrophages and astrocytes of apoptotic cells. It's a receptor for C1q, an eat-me signal, that binds phosphatidylserine expressed on the surface of apoptotic cells

Target

  • Target
  • GPC3
  • Target Species
  • Human
  • Clone
  • YP7
  • Host
  • Mouse
  • Gene Name
  • Glypican 3
  • Introduction
  • Cell surface heparan sulfate proteoglycans are composed of a membrane-associated protein core substituted with a variable number of heparan sulfate chains. Members of the glypican-related integral membrane proteoglycan family (GRIPS) contain a core protein anchored to the cytoplasmic membrane via a glycosyl phosphatidylinositol linkage. These proteins may play a role in the control of cell division and growth regulation. The protein encoded by this gene can bind to and inhibit the dipeptidyl peptidase activity of CD26, and it can induce apoptosis in certain cell types. Deletion mutations in this gene are associated with Simpson-Golabi-Behmel syndrome, also known as Simpson dysmorphia syndrome. Alternative splicing results in multiple transcript variants.
  • Alternative Names
  • SGB; DGSX; MXR7; SDYS; SGBS; OCI-5; SGBS1; GTR2-2; GPC3; Glypican 3

Customize Your CAR Products

Customize Your CAR Products
Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-GPC3 (YP7) ICD(Megf10) CAR THP1 Cell Line (CARTHP-W0802). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

CAR Vector Products

CAR Viral Particles

CAR Cell Products

CAR mRNA

CAR-MA Vector Products

CAR Animal Cells

CAR-MA Cell Products

Online Inquiry
Products
Global Services
Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.
Copyright © 2024 Creative Biolabs. All Rights Reserved
Cart
    Go to checkout